BMI-associated anti-apolipoprotein A-1 positivity in healthy adults after mRNA-vaccination against COVID-19

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083821" target="_blank" >RIV/00023001:_____/23:00083821 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/23:10458567 RIV/00216208:11120/23:43925317 RIV/00064173:_____/23:43925317

Výsledek na webu

<a href="https://www.mdpi.com/2076-393X/11/3/670" target="_blank" >https://www.mdpi.com/2076-393X/11/3/670</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/vaccines11030670" target="_blank" >10.3390/vaccines11030670</a>

Jazyk výsledku

angličtina

Název v původním jazyce

BMI-associated anti-apolipoprotein A-1 positivity in healthy adults after mRNA-vaccination against COVID-19

Popis výsledku v původním jazyce

Elevated anti-apolipoprotein A-1 (AAA1) antibody levels associated with cardiovascular risk have been observed in previously SARS-CoV-2-infected or COVID-19-vaccinated individuals. Since patient safety is generally a priority in vaccination, we sought to investigate AAA1 antibody levels in healthy adults after mRNA vaccination. We conducted a prospective cohort study in healthy adult volunteers recruited from military workers of the Transport Air Base in Prague who had received two doses of mRNA vaccines. Anti-apolipoprotein A-1 antibody levels were determined using ELISA from serum samples obtained at three and four time points after the first and second vaccine doses, respectively, within almost 17 weeks of follow-up. The transient AAA1 positivity rate achieved 24.1% (95% confidence interval CI: 15.4-34.7%), i.e., 20 out of 83 participants had at least one positive post-vaccination sample, with a repeat positivity confirmed in only 5 of them. This rate was associated with a BMI &gt; 26 kg/m(2), as documented by an adjusted odds ratio of 6.79 (95% CI: 1.53-30.01). In addition, the highest positivity rate of 46.7% (21.3-73.4%) was observed in obese subjects with &gt;30 kg/m(2). Since the incidence rate of AAA1 positivity remained unchanged after the first and second vaccine doses, any relationship between AAA1 positivity and mRNA vaccination was inconclusive. The present study showed a transient AAA1 positivity rate associated with overweight or obesity without a proven association with mRNA vaccination.

Název v anglickém jazyce

BMI-associated anti-apolipoprotein A-1 positivity in healthy adults after mRNA-vaccination against COVID-19

Popis výsledku anglicky

Elevated anti-apolipoprotein A-1 (AAA1) antibody levels associated with cardiovascular risk have been observed in previously SARS-CoV-2-infected or COVID-19-vaccinated individuals. Since patient safety is generally a priority in vaccination, we sought to investigate AAA1 antibody levels in healthy adults after mRNA vaccination. We conducted a prospective cohort study in healthy adult volunteers recruited from military workers of the Transport Air Base in Prague who had received two doses of mRNA vaccines. Anti-apolipoprotein A-1 antibody levels were determined using ELISA from serum samples obtained at three and four time points after the first and second vaccine doses, respectively, within almost 17 weeks of follow-up. The transient AAA1 positivity rate achieved 24.1% (95% confidence interval CI: 15.4-34.7%), i.e., 20 out of 83 participants had at least one positive post-vaccination sample, with a repeat positivity confirmed in only 5 of them. This rate was associated with a BMI &gt; 26 kg/m(2), as documented by an adjusted odds ratio of 6.79 (95% CI: 1.53-30.01). In addition, the highest positivity rate of 46.7% (21.3-73.4%) was observed in obese subjects with &gt;30 kg/m(2). Since the incidence rate of AAA1 positivity remained unchanged after the first and second vaccine doses, any relationship between AAA1 positivity and mRNA vaccination was inconclusive. The present study showed a transient AAA1 positivity rate associated with overweight or obesity without a proven association with mRNA vaccination.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

<a href="/cs/project/NU22-A-125" target="_blank" >NU22-A-125: Vliv SARS-CoV-2 na časný výskyt akutního koronárního syndromu, jeho komplikací a polyvaskulárního postižení.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Vaccines (Basel) [online]

ISSN

2076-393X

e-ISSN

2076-393X

Svazek periodika

11

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

8

Strana od-do

"art. no. 670"

Kód UT WoS článku

000959161200001

EID výsledku v databázi Scopus

2-s2.0-85152073316